UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
OCULAR SCIENCES, INC.
-----------------------------------------------------------------
(Name of Issuer)
COMMON STOCK
-----------------------------------------------------------------
(Title of Class of Securities)
675744 10 6
-----------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this
statement [ ]. (A fee is not required only if the filing person:
(1) has a previous statement on file reporting beneficial
ownership of more than five percent of the class of securities
described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of
such class.) (See Rule 13d-7).
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in
a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 14 pages
<PAGE>
SCHEDULE 13G
----------------------- -------------------------
CUSIP No. 675744 10 6 Page 2 of 14 Pages
------------- ----- -----
----------------------- -------------------------
-----------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
GALEN PARTNERS, L. P.
-----------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
-----------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
-----------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
-----------------------------------------------------------------
5 SOLE VOTING POWER
682,564
-----------------------------------------------------------------
6 SHARED VOTING POWER
- 0 -
-----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
682,564
-----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
- 0 -
-----------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
682,564
-----------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [X]
Excludes 11,010 shares held of record by Galen Associates
and 20,016 shares subject to options that are currently
exercisable by William R. Grant.
-----------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.02%
-----------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
-----------------------------------------------------------------
<PAGE>
SCHEDULE 13G
----------------------- -------------------------
CUSIP No. 675744 10 6 Page 3 of 14 Pages
------------- ----- -----
----------------------- -------------------------
-----------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
GALEN PARTNERS INTERNATIONAL, L.P.
-----------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
-----------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-----------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
-----------------------------------------------------------------
5 SOLE VOTING POWER
70,299
-----------------------------------------------------------------
6 SHARED VOTING POWER
- 0 -
-----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
70,299
-----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
- 0 -
-----------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
70,299
-----------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [X]
Excludes 11,010 shares held of record by Galen Associates
and 20,016 shares subject to options that are currently
exercisable by William R. Grant.
-----------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.31%
-----------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
-----------------------------------------------------------------
<PAGE>
SCHEDULE 13G
----------------------- -------------------------
CUSIP No. 675744 10 6 Page 4 of 14 Pages
------------- ----- -----
----------------------- -------------------------
-----------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
GALEN ASSOCIATES
-----------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
-----------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-----------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
-----------------------------------------------------------------
5 SOLE VOTING POWER
11,010
-----------------------------------------------------------------
6 SHARED VOTING POWER
- 0 -
-----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
11,010
-----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
- 0 -
-----------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11,010
-----------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [X]
Excludes 20,016 shares subject to options that are currently
exercisable by William R. Grant.
-----------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
.05%
-----------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
-----------------------------------------------------------------
<PAGE>
SCHEDULE 13G
---------------------- -------------------------
CUSIP No. 675744 10 6 Page 5 of 14 Pages
------------ ----- -----
---------------------- -------------------------
-----------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
WILLIAM R. GRANT
-----------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
-----------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
-----------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
-----------------------------------------------------------------
5 SOLE VOTING POWER
62,575
-----------------------------------------------------------------
6 SHARED VOTING POWER
- 0 -
-----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
82,591, including 20,016 shares subject to options that
are currently exercisable.
-----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
- 0 -
-----------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
82,591, including 20,016 shares subject to options that are
currently exercisable.
-----------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [ ]
-----------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.36%
-----------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IN
-----------------------------------------------------------------
<PAGE>
The initial Schedule 13G, dated February 12, 1998, is
hereby amended, on behalf of each Reporting Person, to reflect
(i) the sale by the Reporting Persons, Galen Partners, L.P. and
Galen Partners International, L.P., of an aggregate of 1,001,196
shares of Common Stock, as of March 24, 1998, pursuant to an
underwritten public offering, (ii) the pro rata distribution by
the Reporting Persons, Galen Partners, L.P and Galen Partners
International, L.P., to their respective partners of an aggregate
of 700,000 shares of Common Stock, as of April 27, 1999, and
(iii) the pro rata distribution by the Reporting Persons, Galen
Partners, L.P. and Galen Partners International, L.P., to their
respective partners of an aggregate of 500,000 shares of Common
Stock, as of May 11, 1999. Set forth below, as identified by
Reporting Person, is an amended Item 4 showing the ownership of
shares of Common Stock following such transactions.
ITEM 1. ISSUER'S NAME AND ADDRESS OF PRINCIPAL EXECUTIVE OFFICES:
--------------------------------------------------------
(a) Ocular Sciences, Inc.
(b) 475 Eccles Avenue
South San Francisco, CA 94080
ITEM 2. INFORMATION CONCERNING PERSON FILING:
------------------------------------
(a) Galen Partners, L.P.
(b) 610 Fifth Avenue, 5th Floor
Rockefeller Center
New York, NY 10020
(c) Delaware
(d) Common Stock
(e) 675744 10 6
ITEM 4. OWNERSHIP:
---------
(a) 682,564
(b) 3.02%
(c) (i) Sole power to vote or to direct vote:
682,564 shares
(ii) Shared power to vote or to direct vote:
0 shares
(iii) Sole power to dispose or to direct the
disposition: 682,564 shares
(iv) Shared power to dispose or to direct the
disposition: 0 shares
Page 6 of 14 pages
<PAGE>
ITEM 1. ISSUER'S NAME AND ADDRESS OF PRINCIPAL EXECUTIVE OFFICES:
--------------------------------------------------------
(a) Ocular Sciences, Inc.
(b) 475 Eccles Avenue
South San Francisco, CA 94080
ITEM 2. INFORMATION CONCERNING PERSON FILING:
------------------------------------
(a) Galen Partners International, L.P.
(b) 610 Fifth Avenue, 5th Floor
Rockefeller Center
New York, NY 10020
(c) Delaware
(d) Common Stock
(e) 675744 10 6
ITEM 4. OWNERSHIP:
---------
(a) 70,299
(b) 0.31%
(c) (i) Sole power to vote or to direct vote:
70,299 shares
(ii) Shared power to vote or to direct vote:
0 shares
(iii) Sole power to dispose or to direct the
disposition: 70,299 shares
(iv) Shared power to dispose or to direct the
disposition: 0 shares
Page 7 of 14 pages
<PAGE>
ITEM 1. ISSUER'S NAME AND ADDRESS OF PRINCIPAL EXECUTIVE OFFICES:
--------------------------------------------------------
(a) Ocular Sciences, Inc.
(b) 475 Eccles Avenue
South San Francisco, CA 94080
ITEM 2. INFORMATION CONCERNING PERSON FILING:
------------------------------------
(a) Galen Associates
(b) 610 Fifth Avenue, 5th Floor
Rockefeller Center
New York, NY 10020
(c) Delaware
(d) Common Stock
(e) 675744 10 6
ITEM 4. OWNERSHIP:
---------
(a) 11,010
(b) 0.05%
(c) (i) Sole power to vote or to direct vote:
11,010 shares
(ii) Shared power to vote or to direct vote:
0 shares
(iii) Sole power to dispose or to direct the
disposition: 11,010 shares
(iv) Shared power to dispose or to direct the
disposition: 0 shares
Page 8 of 14 pages
<PAGE>
ITEM 1. ISSUER'S NAME AND ADDRESS OF PRINCIPAL EXECUTIVE OFFICES:
--------------------------------------------------------
(a) Ocular Sciences, Inc.
(b) 475 Eccles Avenue
South San Francisco, CA 94080
ITEM 2. INFORMATION CONCERNING PERSON FILING:
------------------------------------
(a) William R. Grant
(b) 610 Fifth Avenue, 5th Floor
Rockefeller Center
New York, NY 10020
(c) U.S.A.
(d) Common Stock
(e) 675744 10 6
ITEM 4. OWNERSHIP:
---------
(a) 62,575
(b) 0.36%
(c) (i) Sole power to vote or to direct vote:
62,575 shares
(ii) Shared power to vote or to direct vote:
0 shares
(iii) Sole power to dispose or to direct the
disposition: 82,591 including 20,016
shares subject to options that are
currently exercisable
(iv) Shared power to dispose or to direct the
disposition: 0 shares
Page 9 of 14 pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.
May 12, 1999
-----------------------------------
Date
GALEN PARTNERS, L.P.
By: BGW Partners, L.P.
General Partner
By: /s/ Bruce F. Wesson
-------------------------------
Name: Bruce F. Wesson
Title: General Partner
GALEN PARTNERS INTERNATIONAL, L.P.
By: BGW PARTNERS, L.P.
General Partner
By: /s/ Bruce F. Wesson
-------------------------------
Name: Bruce F. Wesson
Title: General Partner
Page 10 of 14 pages
<PAGE>
GALEN ASSOCIATES
By: WESSON ENTERPRISES, INC.
General Partner
By: /s/ Bruce F. Wesson
-------------------------------
Name: Bruce F. Wesson
Title: President
/s/ William R. Grant
-----------------------------------
William R. Grant
Page 11 of 14 pages
<PAGE>
EXHIBIT INDEX
Sequentially
Exhibit Document Description Numbered Page
------- -------------------- -------------
A Agreement of Joint Filing 13
Page 12 of 14 pages
EXHIBIT A
Agreement of Joint Filing
Each of the undersigned hereby agrees that they are filing
jointly pursuant to Rule 13d-1(f)(1) of the Securities Exchange
Act of 1934, as amended, the Statement dated May 10, 1999,
containing the information required by Schedule 13G, for the
shares of Common Stock of Ocular Sciences, Inc. which are held of
record by Galen Partners, L.P., Galen Partners International,
L.P., Galen Associates and William R. Grant and beneficially
owned by the undersigned.
Each of the undersigned hereby expressly disclaims beneficial
ownership of any of such shares as to which he or it does not
have an actual pecuniary interest.
DATED: May 12, 1999
GALEN PARTNERS, L.P.
By: BGW PARTNERS, L.P.
General Partner
By: /s/ Bruce F. Wesson
-------------------------
Name: Bruce F. Wesson
Title: General Partner
GALEN PARTNERS INTERNATIONAL, L.P.
By: BGW PARTNERS, L.P.
General Partner
By: /s/ Bruce F. Wesson
-------------------------------
Name: Bruce F. Wesson
Title: General Partner
Page 13 of 14 pages
<PAGE>
GALEN ASSOCIATES
By: WESSON ENTERPRISES, INC.
General Partner
By: /s/ Bruce F. Wesson
-------------------------------
Name: Bruce F. Wesson
Title: President
/s/ William R. Grant
-----------------------------------
William R. Grant
Page 14 of 14 pages
